Sera Prognostics, Inc., (SERA): Price and Financial Metrics
GET POWR RATINGS... FREE!
SERA Stock Price Chart Interactive Chart >
SERA Price/Volume Stats
| Current price | $1.53 | 52-week high | $15.50 |
| Prev. close | $1.52 | 52-week low | $1.43 |
| Day low | $1.53 | Volume | 184 |
| Day high | $1.53 | Avg. volume | 73,418 |
| 50-day MA | $2.48 | Dividend yield | N/A |
| 200-day MA | $7.13 | Market Cap | 47.27M |
Sera Prognostics, Inc., (SERA) Company Bio
Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Latest SERA News From Around the Web
Below are the latest news stories about Sera Prognostics Inc that investors may wish to consider to help them evaluate SERA as an investment opportunity.
SERA PROGNOSTICS PRESENTATION RESCHEDULED FOR CITI 2022 HEALTHCARE CONFERENCESera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that its presentation at the virtual Citi 2022 Healthcare Conference: Services, MedTech, Life Science Tools & HCIT, to be held February 23-24, 2022, has been rescheduled. Gregory C. Critchfield, M.D., M.S., Chairman and CEO, will provide a company update and discuss Sera's latest achievemen |
SERA PROGNOSTICS TO PRESENT AT UPCOMING FEBRUARY INVESTOR CONFERENCESSera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the upcoming virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the virtual Citi 2022 Healthcare Conference: Services, MedTech, Life Science Tools & HCIT. Gregory C. Critchfield, M.D., M.S., Chairman and CEO, will provide a |
Sera Prognostics in pact with MultiPlan to expand market for PreTRM TestSera Prognostics < |
SERA PROGNOSTICS ANNOUNCES NEW AGREEMENT WITH MULTIPLAN, EXPANDING PATIENT ACCESS TO THE PRETRM® TESTSera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the execution of an agreement with MultiPlan, for participation in its PHCS and MultiPlan Networks. The agreement will help expand access to the PreTRM® Test, the company's proprietary proteomic blood test for measuring a woman's risk of spontaneous preterm birth, to allow more timely inter |
SERA PROGNOSTICS ADDED TO NASDAQ BIOTECHNOLOGY INDEXSera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI). The addition is based on the annual reconstitution of the index announced by Nasdaq and will become effective prior to the U.S. stock market open on Monday, December 20, 2021. |
SERA Price Returns
| 1-mo | -32.00% |
| 3-mo | -73.02% |
| 6-mo | -86.09% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -77.73% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...